All new content! Use PNCB's follow-up to our bestselling psychopharmacology module to strengthen and expand your knowledge. This module is supported by a respected AAP text (purchased separately with a discount) that offers practical guidance for prescribing and/or monitoring psychopharmacotherapy for children and adolescents. Module topics include ADHD, depression, OCD, anxiety-related disorders, autism, and more. Contraindications, U.S. boxed warnings, adverse effects, drug-drug interactions, toxicities of different agents, and off-label use of select medications are addressed.
7.5 pharmacology contact hours accredited by NAPNAP (7.5 related to psychopharmacology) (1.5 related to controlled substances).
$35 for the questions/CE portion of this Pediatric Updates module.
*UPDATED* Reference Information This module's reference is a single textbook, Pediatric Psychopharmacology for Primary Care, which is sold separately on The American Academy of Pediatrics (AAP) website. The First Edition of this textbook is no longer available on the AAP website as of 10/11/18. You can proceed with ordering the second edition. There are no links to peer-reviewed articles as in other Pediatric Updates. Textbook cost is $70.36 (before taxes and shipping) when you use the 20% discount code PNCBMA0415. PNCB does not receive any revenue from AAP for textbook purchases. PNCB has confirmed that you may use either edition to complete this Pediatric Updates module.
Answers are due 150 days from order process date.
Pilot testers had this to say about the textbook:
Will definitely use the text in my office practice.
I LOVE the book. It is very concise and informative.
I was impressed about how the meds were grouped according to type e.g., stimulants.
Excellent text. Text and module provide an excellent resource and comprehensive testing for psychopharmacology!
I love the practice of using an entire focused text as the reference.
Q. Use of an amphetamine to treat ADHD is CONTRAINDICATED for a child with which of the following conditions? SELECT THREE (3) A. asthma B. hyperthyroidism C. chronic kidney injury D. moderate hypertension E. symptomatic cardiovascular disease